‹ All stocks

Unicycive Therapeutics

UNCY · NASDAQ · Healthcare

$4.55

▼ $0.15 (-3.19%)

1D 7D 1M 3M 1Y All

Day range

$4.55 – $4.76

Year range

$3.93 – $8.74

Open

$4.71

Previous close

$4.70

Market cap

$121.48M

Volume (24h)

$1.0M

Volume (52w)

$4.71M

Performance

▼ -1.94%

▼ -9.54%

▼ -16.21%

▼ -29.46%

▼ -1.09%

YTD

▼ -21.55%

▼ -45.18%

▼ -83.98%

All-time

▼ -90.90%

Key statistics

P/E ratio

-2.60

EPS (TTM)

$-1.75

Dividend yield

—

Dividend (TTM)

—

Payout ratio

—

Shares outstanding

26.7M

About Unicycive Therapeutics

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Visit website

Country: United States of America

LLY Eli Lilly and Company	$1156.42	0.49%
JNJ Johnson & Johnson	$254.52	-0.58%
ABBV AbbVie	$262.04	0.29%
MRK Merck & Co.	$139.70	-2.76%
UNH UnitedHealth Group Incorp…	$371.61	-0.19%